All News

CURE spoke with John O. Mascarenhas about advancements in the care of myelofibrosis.

I think about how much I have changed in two years time, and how cancer has changed the trajectory of my life.

We lost a good man to cancer not that long ago but you most certainly didn’t hear about it. He was a teacher, husband, father, mentor, coach and survivor right up to the end.

Gilotrif (afatinib) recently gained approval for some patients with non–small cell lung cancer (NSCLC).

Girls treated for cancer with radiotherapy in their childhood may grow up to have a higher risk of developing breast cancer if they have certain genetic mutations.

Insurance companies often try to defend their decisions to deny medical claims but patients have a right to appeal.

"Although the patients are super important, the siblings are just as important and play a crucial role in their brother or sister’s fight. Time and time again, I found myself telling my sister’s story when I was asked to share my story."

Looking for positives signs of inspiration can help with personal healing after a cancer diagnosis.

Though we are each unique, connecting with fellow cancer survivors helps, says two-time survivor Barbara Tako.

According to an analysis of the phase 3 GOG-0218 trial, patients who had ovarian cancer and mutations in homologous recombination (HR) genes showed improved survival rates when compared to patients without the mutations.

There will be another #Hcchat on Twitter this month with special guest Ellen Matloff.

What is in your chemo tote? What should you give somebody who is getting ready to use one? Make a list, and check it twice.

Opdivo might be the first PD-1 inhibitor approved for a hematologic malignancy after FDA review and approval.

CURE talks with Zsofia K. Stadler, a medical oncologist at Memorial Sloan Kettering Cancer Center, about screening for certain patients with CRC.

A priority review designation was granted to Keytruda for some patients with head and neck cancer. A decision submission is due in August.

Patients and caregivers benefit from informed and sensitive decisions about treatment options. How do you provide the best possible care while successfully balancing personalities and emotions?

Phase 3 studies are giving investigators hope that Lynparza (olaparib) will gain FDA approval for the treatment of ovarian cancer, according to Ursula A. Matulonis.

An interview with Jason Luke, an assistant professor of Medicine at the University of Chicago Medicine, reveals that he thinks immunotherapy should become a main treatment for many patients with melanoma.

Immunotherapy for the treatment of NSCLC will eventually be used in all settings, according to Edward Kim.

Eighteen months into a metastatic breast cancer diagnosis, and my thinking--and life--has changed in an unexpected way.

In the analysis, there was as much as a 92 percent difference in median overall survival (OS) seen between patients treated in randomized controlled trials and "real world" data.